Know Cancer

or
forgot password

A Phase I/II Trial: Docetaxel, Irinotecan, and Carboplatin in the Treatment of Extensive Stage Small Cell Lung Carcinoma


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Both
Non-small Cell Lung Cancer, Extensive Stage Unresectable

Thank you

Trial Information

A Phase I/II Trial: Docetaxel, Irinotecan, and Carboplatin in the Treatment of Extensive Stage Small Cell Lung Carcinoma


A phase I/II dose escalating study to determine the maximum tolerated dose of docetaxel when
given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.


Inclusion Criteria:



- 18 years or older unresectable lung cancer measurable or evaluable lesions Karnofsky
PS greater than or equal to 60%

Exclusion Criteria:

- untreated CNS metastases

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.

Principal Investigator

Shawn Glisson, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Kentuckiana Cancer Institute

Authority:

United States: Institutional Review Board

Study ID:

1047791

NCT ID:

NCT00264134

Start Date:

June 2003

Completion Date:

October 2005

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Extensive Stage Unresectable
  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Small Cell Lung Carcinoma

Name

Location

Kentuckiana Cancer InstituteLouisville, Kentucky  40202